Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American ...
Robust preclinical data supports breadth and growth of Landos’ autoimmune-focused pipeline Company expects to submit an IND for omilancor as a topical treatment for psoriasis in 2H 2021 Company expects to submit an IND for PX-69 as an oral treatment for …